Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Adma Biologics (ADMA) Interest & Investment Income (2016 - 2025)

Adma Biologics' Interest & Investment Income history spans 13 years, with the latest figure at $487000.0 for Q4 2025.

  • For Q4 2025, Interest & Investment Income fell 18.56% year-over-year to $487000.0; the TTM value through Dec 2025 reached $1.9 million, down 10.78%, while the annual FY2025 figure was $1.9 million, 10.78% down from the prior year.
  • Interest & Investment Income reached $487000.0 in Q4 2025 per ADMA's latest filing, up from $376000.0 in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $666000.0 in Q3 2024 to a low of $2269.0 in Q2 2022.
  • Average Interest & Investment Income over 5 years is $283150.0, with a median of $380000.0 recorded in 2024.
  • Peak YoY movement for Interest & Investment Income: plummeted 91.11% in 2021, then skyrocketed 25116.32% in 2023.
  • A 5-year view of Interest & Investment Income shows it stood at $2759.0 in 2021, then fell by 12.03% to $2427.0 in 2022, then surged by 25116.32% to $612000.0 in 2023, then decreased by 2.29% to $598000.0 in 2024, then fell by 18.56% to $487000.0 in 2025.
  • Per Business Quant, the three most recent readings for ADMA's Interest & Investment Income are $487000.0 (Q4 2025), $376000.0 (Q3 2025), and $400000.0 (Q2 2025).